Journal
ONCOTARGET
Volume 6, Issue 28, Pages 26472-26482Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4500
Keywords
Merkel cell carcinoma; neuron specific enolase; chromogranin A; circulating tumor cells; EpCAM
Categories
Funding
- Olympia-Morata-Program of the University of Heidelberg
- National Institutes of Health Intramural Research Program, Center of Cancer Research, National Cancer Institute
Ask authors/readers for more resources
Background: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer. Although used to monitor MCC patients, the clinical utility of neuron-specific enolase (NSE) and chromogranin A (ChrA) blood levels is untested. EpCAM-positive circulating tumor cells (CTC) reflect disease status in several epithelial tumors. Here we investigate the use of NSE and ChrA blood levels and CTC counts as biomarkers for MCC disease behavior. Methods: NSE and ChrA blood levels from 60 patients with MCC were retrospectively analyzed; 30 patients were additionally screened for CTC. Biomarker values were correlated to clinical parameters. Results: Despite routine use by some physicians, NSE and ChrA blood levels did not correlate with progression free survival, disease specific survival, or MCC recurrence. We found CTC in 97% of tested MCC patients. CTC counts were elevated in patients with active disease, suggesting their potential use in monitoring MCC. Conclusion: NSE and ChrA levels were not effective in predicting outcomes or detecting recurrences of MCC. In contrast, CTC counts have potential utility as a biomarker for MCC disease behavior.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available